Merck has issued a letter to healthcare professionals letting them know that Nasonex (mometasone furoate monohydrate) Nasal Spray 50mcg is currently out of stock due to a manufacturing issue. The company anticipates having supply available by either November or December of this year.
Nasonex is indicated for the treatment of seasonal and perennial allergic rhinitis symptoms in patients ≥2yrs of age and for the prophylaxis of seasonal allergic rhinitis symptoms in patients ≥12yrs of age. It is also approved for the treatment of nasal polyps in patients aged ≥18 years.
For more information visit Merck.com.